Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Capital Expenditures (2020 - 2025)

Sight Sciences (SGHT) has 6 years of Capital Expenditures data on record, last reported at -$156000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 213.87% year-over-year to -$156000.0; the TTM value through Dec 2025 reached $224000.0, down 41.82%, while the annual FY2025 figure was $224000.0, 41.82% down from the prior year.
  • Capital Expenditures reached -$156000.0 in Q4 2025 per SGHT's latest filing, down from $170000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $342000.0 in Q2 2022 and bottomed at -$156000.0 in Q4 2025.
  • Average Capital Expenditures over 5 years is $167526.3, with a median of $157000.0 recorded in 2021.
  • The widest YoY moves for Capital Expenditures: up 233.33% in 2025, down 213.87% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $157000.0 in 2021, then decreased by 17.83% to $129000.0 in 2022, then soared by 104.65% to $264000.0 in 2023, then tumbled by 48.11% to $137000.0 in 2024, then tumbled by 213.87% to -$156000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$156000.0 in Q4 2025, $170000.0 in Q3 2025, and $210000.0 in Q2 2025.